Pfizer Inc

Pfizer Inc

PFE · NYSE · Healthcare / Drug Manufacturers - General

28.89USD+0.06 (+0.21%)

Price History

Full chart

Market Stats

Previous Close28.83
Open28.92
Day Range28.62 – 28.99
52-Week Range22.41 – 30.99
Volume21.55M
Market Cap167.52B
P/E (TTM)41.99
Forward P/E10.27
EPS0.70
Dividend Yield5.85%
Beta0.30
50-Day Avg28.74
200-Day Avg26.91

About

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - General
  • CEODr. Albert Bourla D.V.M., Ph.D.
  • Employees75.00K
  • Headquarters66 Hudson Boulevard East, New York, NY, United States, 10001-2192, USA
  • Websitehttps://www.pfizer.com

Leadership

  • Dr. Albert Bourla D.V.M., Ph.D.Chairman of the Board & CEO · b. 1962
  • Dr. Chris Boshoff FMedSci, M.D., Ph.D.Chief Scientific Officer and President of Research & Development · b. 1964
  • Mr. Douglas M. LanklerExecutive VP & Chief Legal Officer · b. 1966
  • Mr. Aamir MalikExecutive VP & Chief U.S. Commercial Officer · b. 1976
  • Ms. Jennifer B. DamicoSenior VP, Controller & Principal Accounting Officer · b. 1969
  • Mr. Dennis P. HancockExecutive VP & Chief Information Officer
  • Ms. Francesca M. DeMartinoChief Investor Relations Officer
  • Ms. Payal Sahni BecherChief People Experience Officer & Executive VP · b. 1975
  • Dr. Michael S. Vincent M.D., Ph.D.Senior VP and Chief Scientific Officer of Inflammation & Immunology
  • Dr. Jeffrey Settleman Ph.D.Chief Scientific Officer of Oncology

Financials

Income Statement

Currency: USD1986-12-311987-12-311988-12-311989-12-311990-12-311991-12-311992-12-311993-12-311994-12-311995-12-311996-12-311997-12-311998-12-311999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue4.48B4.92B5.39B5.67B6.41B6.95B7.23B7.48B8.28B10.02B9.86B11.05B23.23B27.38B29.36B29.02B32.29B44.74B48.99B47.41B48.37B48.42B48.30B50.01B65.17B61.03B54.66B51.58B49.60B48.85B52.82B52.55B40.83B40.91B41.65B81.29B101.17B59.55B63.63B62.58B
Growth (%)-+9.92%+9.46%+5.31%+12.95%+8.49%+4.03%+3.42%+10.75%+21.01%-1.57%+12.07%+110.14%+17.84%+7.23%-1.13%+11.27%+38.53%+9.50%-3.23%+2.04%+0.10%-0.25%+3.55%+30.31%-6.34%-10.45%-5.62%-3.84%-1.52%+8.13%-0.53%-22.31%+0.20%+1.82%+95.16%+24.46%-41.14%+6.84%-1.65%
Cost of Revenue1.57B1.73B1.83B1.86B2.03B1.96B1.76B1.51B1.63B1.79B1.34B1.35B4.21B4.66B5.01B3.82B4.01B9.59B6.39B7.23B7.64B11.24B8.11B8.89B14.79B12.50B9.82B9.59B9.58B9.65B12.32B11.23B8.99B8.05B8.48B30.82B34.34B24.95B17.85B16.07B
Gross Profit2.90B3.18B3.56B3.82B4.37B4.99B5.47B5.96B6.65B8.23B8.53B9.71B19.02B22.71B24.35B25.20B28.28B35.15B42.60B40.17B40.73B37.18B40.18B41.12B50.38B48.53B44.84B42.00B40.03B39.20B40.50B41.32B31.84B32.85B33.17B50.47B66.83B34.60B45.78B46.51B
Gross Margin64.85%64.74%66.10%67.29%68.24%71.85%75.65%79.76%80.36%82.14%86.46%87.81%81.86%82.97%82.94%86.83%87.57%78.57%86.95%84.74%84.21%76.79%83.20%82.23%77.31%79.52%82.03%81.42%80.69%80.25%76.67%78.63%77.99%80.31%79.63%62.08%66.05%58.10%71.94%74.33%
Operating Expense1.94B2.24B2.55B2.85B3.32B3.74B4.03B5.05B4.68B5.67B5.79B6.63B13.66B15.75B15.78B14.59B16.06B24.78B26.17B25.97B26.45B26.84B28.59B25.40B33.82B31.73B27.76B25.63B26.53B26.23B26.79B27.25B25.11B25.54B24.34B30.23B28.71B30.18B30.84B29.11B
Operating Income959.70M940.80M1.01B968.20M1.05B1.25B1.44B913.30M1.97B2.56B2.74B3.07B5.35B6.96B8.57B10.61B12.22B10.37B16.43B14.21B14.28B10.34B11.60B15.72B16.56B16.81B17.07B16.37B13.50B12.98B13.71B14.07B6.73B7.31B8.83B20.23B38.12B4.42B14.94B17.41B
Operating Margin21.44%19.12%18.79%17.07%16.45%18.04%19.96%12.21%23.82%25.55%27.81%27.80%23.03%25.43%29.19%36.57%37.84%23.17%33.53%29.97%29.53%21.35%24.01%31.43%25.41%27.54%31.24%31.73%27.21%26.56%25.95%26.78%16.48%17.87%21.20%24.89%37.67%7.42%23.48%27.82%
EBITDA1.11B1.10B1.21B1.18B1.28B1.50B1.71B1.17B2.26B2.93B3.10B3.50B6.15B7.87B9.54B11.59B13.26B14.39B21.52B19.78B19.57B15.54B15.30B16.82B19.67B22.19B20.42B23.54B19.14B15.32B15.29B19.84B11.06B18.65B13.26B30.79B41.03B9.56B18.13B16.78B
EBITDA Margin24.73%22.42%22.40%20.72%19.96%21.55%23.61%15.67%27.34%29.28%31.45%31.67%26.46%28.74%32.49%39.92%41.05%32.17%43.93%41.73%40.47%32.09%31.68%33.63%30.18%36.35%37.36%45.63%38.58%31.36%28.95%37.77%27.09%45.59%31.84%37.88%40.55%16.05%28.49%26.82%
Net Income660.00M690.20M791.30M681.10M801.20M722.10M810.90M657.50M1.30B1.57B1.93B2.21B4.63B4.95B3.73B7.79B9.13B3.91B11.36B8.09B19.34B8.14B8.10B8.63B8.26B10.01B14.57B22.00B9.13B6.96B7.21B21.31B11.15B16.03B9.16B21.98B31.37B2.12B8.03B7.77B
Net Income Margin14.75%14.03%14.69%12.01%12.51%10.39%11.22%8.79%15.68%15.70%19.56%20.02%19.94%18.09%12.69%26.83%28.26%8.74%23.19%17.06%39.98%16.82%16.78%17.27%12.67%16.40%26.66%42.65%18.42%14.25%13.66%40.55%27.32%39.18%21.99%27.04%31.01%3.56%12.62%12.42%
R&D----------1.57B1.80B3.31B4.04B4.43B4.78B5.21B7.49B7.51B7.26B7.60B8.09B8.58B7.84B9.48B8.68B7.48B6.68B8.39B7.69B7.89B7.68B7.76B8.38B9.39B13.83B11.43B10.68B10.82B10.44B
R&D as % of Total Revenue----------15.89%16.33%14.23%14.74%15.11%16.46%16.13%16.74%15.34%15.31%15.71%16.71%17.76%15.69%14.55%14.22%13.69%12.95%16.92%15.74%14.94%14.62%19.01%20.50%22.55%17.01%11.30%17.93%17.01%16.68%
Interest Expense000000000000000000347.00M471.00M488.00M397.00M516.00M1.23B1.80B1.68B1.52B1.41B1.36B1.20B1.19B1.27B1.32B1.57B1.45B1.29B1.24B2.21B3.09B2.67B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.71%0.99%1.01%0.82%1.07%2.47%2.76%2.75%2.78%2.74%2.74%2.45%2.25%2.42%3.22%3.85%3.48%1.59%1.22%3.71%4.86%4.27%

Balance Sheet

Currency: USD1986-12-311987-12-311988-12-311989-12-311990-12-311991-12-311992-12-311993-12-311994-12-311995-12-311996-12-311997-12-311998-12-311999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets5.16B6.92B7.64B8.32B9.05B9.63B9.59B9.33B11.10B12.73B14.67B15.34B18.30B20.57B33.51B39.15B46.36B116.78B123.68B117.56B114.84B115.27B111.15B212.95B195.01B188.00B185.80B172.10B169.27B167.46B171.62B171.80B159.42B167.49B154.23B181.48B197.21B226.50B213.40B208.16B
Total Liabilities1.75B3.04B3.34B3.76B3.93B4.57B4.84B5.43B6.74B7.18B7.66B7.06B9.49B17.42B17.43B20.86B26.41B51.40B54.80B51.21B44.11B50.14B53.41B122.50B106.75B105.38B104.12B95.48B97.65B102.46B111.78B100.14B95.66B104.04B90.76B104.01B101.29B137.21B124.90B121.39B
Total Equity3.42B3.88B4.30B4.54B5.09B5.03B4.72B3.87B4.32B5.51B6.95B7.93B8.81B8.89B16.08B18.29B19.95B65.38B68.28B65.63B71.36B65.01B57.56B90.01B87.81B82.19B81.26B76.31B71.62B65.00B59.84B71.66B63.76B63.45B63.47B77.46B95.92B89.29B88.20B86.48B
Cash398.60M1.03B807.50M825.40M870.30M1.32B1.26B729.40M1.46B403.30M1.15B877.00M1.55B2.36B1.10B1.04B1.88B1.52B1.81B2.25B1.83B3.41B2.12B1.98B1.74B3.18B10.08B2.18B3.34B3.64B2.60B1.34B1.14B1.30B1.78B1.94B416.00M2.85B1.04B1.14B
Total Debt556.70M963.80M1.19B1.72B1.69B2.09B1.82B1.75B2.82B2.87B2.92B2.98B3.26B7.07B5.41B8.87B11.81B14.57B18.55B17.94B7.98B13.14B17.28B48.66B44.03B38.94B37.46B36.49B36.68B38.98B42.09B43.48B41.74B52.15B39.84B38.44B35.83B75.04B66.99B67.42B
Net Debt158.10M-67.30M387.10M891.50M822.30M770.10M566.50M1.02B1.37B2.47B1.77B2.10B1.70B4.71B4.31B7.84B9.93B13.05B16.74B15.69B6.15B9.73B15.16B46.68B42.30B35.76B27.38B34.31B33.34B35.34B39.49B41.26B40.13B50.84B36.49B35.05B34.45B72.19B65.95B66.27B

Cash Flow

Currency: USD1989-12-311990-12-311991-12-311992-12-311993-12-311994-12-311995-12-311996-12-311997-12-311998-12-311999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow655.80M860.50M847.60M807.00M1.26B1.49B1.82B2.07B1.63B2.93B3.06B6.20B9.26B10.18B11.74B16.34B14.73B17.59B13.35B18.24B16.59B11.45B20.24B17.05B17.77B16.88B14.51B15.90B16.47B15.83B12.59B14.40B32.58B29.27B8.70B12.74B11.71B
Investing Cash Flow-626.80M-329.00M-125.20M389.90M-196.90M-840.30M-2.34B-937.00M-1.02B-335.00M-2.77B-3.75B-7.22B-4.34B4.84B-9.42B-5.07B5.10B795.00M-12.84B-31.27B-492.00M2.20B6.15B-10.63B-5.65B-2.98B-7.81B-4.74B4.53B-3.94B-4.27B-22.55B-15.78B-32.28B2.65B-1.35B
Financing Cash Flow138.80M-499.90M-262.60M-1.23B-1.57B61.90M-519.10M-382.00M-848.00M-1.92B-1.13B-3.71B-2.10B-5.00B-16.91B-6.63B-9.22B-23.10B-12.61B-6.56B14.48B-11.17B-20.61B-16.00B-14.97B-9.99B-10.23B-8.92B-13.04B-20.44B-8.48B-9.65B-9.82B-14.83B26.07B-17.14B-10.30B
Capital Expenditure456.50M547.50M593.80M674.20M634.20M671.50M696.30M774.00M943.00M1.20B1.56B2.19B2.20B1.76B2.64B2.60B2.11B2.05B1.88B1.70B1.21B1.51B1.66B1.33B1.47B1.58B1.50B2.00B2.22B2.20B2.59B2.79B2.71B3.24B3.91B2.91B2.63B
Free Cash Flow199.30M313.00M253.80M132.80M628.80M817.00M1.13B1.29B686.00M1.73B1.50B4.00B7.06B8.43B9.10B13.74B12.63B15.54B11.47B16.54B15.38B9.94B18.58B15.73B16.30B15.30B13.02B13.90B14.25B13.63B9.99B11.61B29.87B26.03B4.79B9.84B9.08B
Dividends Paid364.00M396.70M437.10M486.50M536.10M594.60M658.50M771.00M881.00M976.00M1.15B2.20B2.71B3.17B4.35B5.08B5.55B6.92B7.97B8.54B5.55B6.09B6.23B6.53B6.58B6.61B6.94B7.32B7.66B7.98B8.04B8.44B8.73B8.98B9.25B9.51B9.77B
FCF to OCF30.39%36.37%29.94%16.46%49.79%54.89%61.77%62.55%42.11%59.10%48.92%64.63%76.22%82.74%77.50%84.08%85.71%88.35%85.92%90.67%92.74%86.79%91.80%92.22%91.75%90.62%89.69%87.43%86.54%86.12%79.39%80.62%91.68%88.94%55.09%77.17%77.54%
Dividend Paid to FCF182.64%126.74%172.22%366.34%85.26%72.78%58.53%59.63%128.43%56.38%76.79%54.87%38.46%37.60%47.85%36.99%43.99%44.51%69.51%51.65%36.07%61.24%33.55%41.55%40.37%43.20%53.32%52.63%53.74%58.53%80.48%72.68%29.22%34.51%192.93%96.72%107.66%

Earnings

Report DateOct 15, 1995Jan 17, 1996Apr 16, 1996Jul 17, 1996Oct 14, 1996Jan 16, 1997Apr 15, 1997Jul 15, 1997Oct 14, 1997Jan 20, 1998Apr 14, 1998Jul 9, 1998Oct 13, 1998Jan 19, 1999Apr 15, 1999Jul 19, 1999Oct 19, 1999Jan 18, 2000Apr 18, 2000Jul 24, 2000Oct 24, 2000Jan 24, 2001Apr 18, 2001Jul 17, 2001Oct 17, 2001Jan 23, 2002Apr 17, 2002Jul 15, 2002Oct 16, 2002Jan 22, 2003Apr 22, 2003Jul 25, 2003Oct 22, 2003Jan 22, 2004Apr 20, 2004Jul 21, 2004Oct 20, 2004Jan 19, 2005Apr 19, 2005Jul 20, 2005Oct 20, 2005Jan 19, 2006Apr 19, 2006Jul 20, 2006Oct 19, 2006Jan 22, 2007Apr 20, 2007Jul 18, 2007Oct 18, 2007Jan 23, 2008Apr 17, 2008Jul 23, 2008Oct 21, 2008Jan 26, 2009Apr 28, 2009Jul 22, 2009Oct 20, 2009Feb 3, 2010May 4, 2010Aug 3, 2010Nov 2, 2010Feb 1, 2011May 3, 2011Aug 2, 2011Nov 1, 2011Jan 31, 2012May 1, 2012Jul 31, 2012Nov 1, 2012Jan 29, 2013Apr 30, 2013Jul 30, 2013Oct 29, 2013Jan 28, 2014May 5, 2014Jul 29, 2014Oct 28, 2014Jan 27, 2015Apr 28, 2015Jul 28, 2015Oct 27, 2015Feb 2, 2016May 3, 2016Aug 2, 2016Nov 1, 2016Jan 31, 2017May 2, 2017Aug 1, 2017Oct 31, 2017Jan 30, 2018May 1, 2018Jul 31, 2018Oct 30, 2018Jan 29, 2019Apr 30, 2019Jul 29, 2019Oct 29, 2019Jan 28, 2020Apr 28, 2020Jul 28, 2020Oct 27, 2020Feb 2, 2021May 4, 2021Jul 28, 2021Nov 2, 2021Feb 8, 2022May 3, 2022Jul 28, 2022Nov 1, 2022Jan 31, 2023May 2, 2023Aug 1, 2023Oct 31, 2023Jan 30, 2024May 1, 2024Jul 30, 2024Oct 29, 2024Feb 4, 2025Apr 29, 2025Aug 5, 2025Nov 4, 2025Feb 3, 2026May 5, 2026Aug 4, 2026Nov 3, 2026
EPS Estimate0.110.110.130.100.130.130.160.120.150.140.180.150.190.170.210.170.210.230.250.220.250.270.310.300.330.340.390.320.380.470.440.290.440.510.510.460.540.590.530.440.480.420.530.480.450.420.570.500.520.470.650.540.600.600.490.460.480.510.530.520.510.460.580.590.560.470.570.550.520.440.550.550.560.530.550.570.550.530.490.520.510.520.550.620.620.510.670.660.650.560.740.740.750.630.750.750.620.580.730.660.710.460.780.981.090.871.571.781.401.040.990.58-0.34-0.180.510.460.610.460.670.570.630.570.720.680.72
EPS Actual0.110.110.140.100.130.130.160.120.150.140.180.170.170.180.210.190.230.250.280.230.270.270.330.300.340.340.390.330.390.480.450.300.470.530.520.470.550.580.540.460.510.510.610.520.540.430.680.420.580.520.610.550.620.640.540.480.510.490.600.620.540.470.600.600.620.500.580.620.530.470.540.560.580.560.570.580.570.540.510.560.600.530.670.640.610.470.690.670.670.620.770.810.780.640.850.800.750.550.800.780.720.420.931.071.341.081.622.041.781.141.230.67-0.170.100.820.601.060.630.920.780.870.660.750.770.87
Surprise0.00%0.00%7.69%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%13.33%-10.53%5.88%0.00%11.76%9.52%8.70%12.00%4.55%8.00%0.00%6.45%0.00%3.03%0.00%0.00%3.13%2.63%2.13%2.27%3.45%6.82%3.92%1.96%2.17%1.85%-1.69%1.89%4.55%6.25%21.43%15.09%8.33%20.00%2.38%19.30%-16.00%11.54%10.64%-6.15%1.85%3.33%6.67%10.20%4.35%6.25%-3.92%13.21%19.23%5.88%2.17%3.45%1.69%10.71%6.38%1.75%12.73%1.92%6.82%-1.82%1.82%3.57%5.66%3.64%1.75%3.64%1.89%4.08%7.69%17.65%1.92%21.82%3.23%-1.61%-7.84%2.99%1.52%3.08%10.71%4.05%9.46%4.00%1.59%13.33%6.67%20.97%-5.17%9.59%18.18%1.41%-8.70%19.23%9.18%22.94%24.14%3.18%14.61%27.14%9.62%24.24%15.52%50.00%155.56%60.78%30.43%73.77%36.96%37.31%36.84%38.10%15.79%4.17%13.24%20.83%
Timing-------Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-----After-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap167.52B
Enterprise Value215.92B
Trailing P/E41.99
Forward P/E10.27
PEG Ratio13.69
Price / Sales2.63
Price / Book1.91
EPS0.70
Book Value15.61
Revenue (TTM)63.62B
Gross Profit (TTM)47.65B
EBITDA24.94B
Profit Margin6.34%
Operating Margin33.38%
Return on Equity4.47%
Return on Assets5.59%
Shares Outstanding5.70B
Shares Float5.69B
Beta0.30
Dividend Yield5.85%
Dividend Rate1.72
Payout Ratio56.39%

Analyst Ratings

Buy
Based on 28 analystsTarget 29.72
  • Strong Buy
    8
  • Buy
    1
  • Hold
    17
  • Sell
    1
  • Strong Sell
    1

Ownership Breakdown

Institutions
68.95%
Insiders
0.10%
Retail / Other
30.95%

Top Institutional Holders

  • BlackRock Inc
    529.67M9.29%
  • Vanguard Capital Management, LLC
    372.15M6.53%
  • State Street Corp
    307.09M5.39%
  • Geode Capital Management, LLC
    135.28M2.37%
  • Vanguard Portfolio Management, LLC
    119.24M2.09%
  • Fisher Asset Management, LLC
    109.07M1.91%
  • Morgan Stanley - Brokerage Accounts
    96.35M1.69%
  • NORGES BANK
    61.51M1.08%
  • Northern Trust Corp
    59.08M1.04%
  • Bank of New York Mellon Corp
    57.88M1.02%
  • Massachusetts Financial Services Company
    56.55M0.99%
  • State Farm Mutual Automobile Ins Co
    54.51M0.96%
  • The Goldman Sachs Group Inc
    52.99M0.93%
  • Charles Schwab Investment Management Inc
    52.55M0.92%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    180.93M3.17%
  • Vanguard 500 Index Investor
    149.69M2.63%
  • iShares Core S&P 500 ETF
    75.84M1.33%
  • Fidelity 500 Index
    73.98M1.30%
  • State Street® SPDR® S&P 500® ETF
    69.72M1.22%
  • Vanguard MStar Value Index Investor
    54.29M0.95%

Dividends

20264×
0.43Nov 6, 20260.43Jul 24, 20260.43May 8, 20260.43Jan 23, 2026
20254×
0.43Nov 7, 20250.43Jul 25, 20250.43May 9, 20250.43Jan 24, 2025
20244×
0.42Nov 8, 20240.42Jul 26, 20240.42May 9, 20240.42Jan 25, 2024
20234×
0.41Nov 9, 20230.41Jul 27, 20230.41May 11, 20230.41Jan 26, 2023
20224×
0.40Nov 3, 20220.40Jul 28, 20220.40May 12, 20220.40Jan 27, 2022
20214×
0.39Nov 4, 20210.39Jul 29, 20210.39May 6, 20210.39Jan 28, 2021

Stock Splits

  • Nov 17, 20201054:1000
  • Jul 1, 19993:1
  • Jul 1, 19972:1
  • Jul 3, 19952:1
  • Apr 1, 19912:1
  • Jul 1, 19832:1